STAT+: FDA approves gene therapy for inherited bleeding disorder hemophilia B

The Food and Drug Administration on Tuesday approved the first gene therapy to treat people with hemophilia B, an inherited bleeding disorder.

The one-time treatment, called Hemgenix, was developed by Dutch biotechnology company UniQure and will be marketed by CSL Behring, the Australian pharmaceutical company.

Stay tuned to STAT+ to read the full story…

Leave a Comment

Your email address will not be published. Required fields are marked *